Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(PP1 Analog II; 1-NM-PP 1)
1-NM-PP1 Chemical Structure
|Product name: 1-NM-PP1|
|Cat. No.: HY-13942|
1NM-PP1(PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors(IC50=28 uM vSrc; 4.2 nM v-Src-as1 I338G).
IC50 Value: 4.2 nM (v-Src-as1 I338G) 
Target: Src Family Kinase
PP1 Analog II, 1NM-PP1 is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors. 1-NM-PP1 is a cell permeable inhibitor of kinases that have been mutated, by a single base substitution, to become 'analog sensitive', as compared to the wild-type kinase. 1-NM-PP1 was first developed to optimally inhibit v-Src-as1, with an I338G substitution, preferentially over v-Src (IC50 = 4.2 nM versus 28 μM, respectively). The homologous mutation in other kinases generated similar analog sensitivity (e.g., IC50 = 3.2 nM for c-Fyn-as1 versus 1.0 μM for c-Fyn; 5.0 nM for CDK2-as1 versus 29 μM for CDK2; 8.0 nM for CAMKII-as1 versus 24 μM for CAMKII). This approach has been used to elucidate functions of several kinases in both mammalian and yeast systems. In addition it has been shown to activate mutants of Ire1, a transmembrane kinase.
|M.Wt||331.41||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO: ≤ 27.5 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||3.0174 mL||15.0871 mL||30.1741 mL|
|5 mM||0.6035 mL||3.0174 mL||6.0348 mL|
|10 mM||0.3017 mL||1.5087 mL||3.0174 mL|
AMG 925 is a potent and selective dual inhibtor of CDK4/FLT3 with IC50s of 1.5 nM and 2.4 nM for CDK4 and FLT3, respectively; with IC50 of 19 nM in MOLM-13 cell.
AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM. It is less potent to CDK5/6.
6-BIO(6-Bromoindirubin-3(acute)-oxime) is a potent and selective inhibitor of GSK-3 and CDK1–cyclinB complex with IC50 of 5 nM /320 nM/83 nM for GSK-3(alpha)(beta)/CDK1/CDK5 respectively.
BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.
Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells.
Ca2(addition) channel agonist 1 is a N-type Ca2(addition) channel activity agonist, with EC50 of 14.23 uM, also inhibits cdk2 kinase activity with EC50 of 3.34 uM.
CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM.
CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection.
CDK9-IN-2 is a novel cyclin-dependent kinase 9(CDK9) inhibitor.
CDK9-IN-6 is a CDK9 inhibitor, refers to Example 399 in WO 2012101062 A1